The development-stage biopharma announced disappointing results from a clinical trial.
Compare UBX Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
Unity Biotechnology, Inc.
News & Analysis: Unity Biotechnology, Inc.
Shares have been mired in a nearly continuous slide for the last year. Is Wall Street's pessimism misplaced?
The longevity-focused biopharma delivered mixed results in its first clinical trial in humans.